We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-2.2%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$378M
AUM Growth
+$11.9M
Cap. Flow
+$42.8M
Cap. Flow %
11.33%
Top 10 Hldgs %
55.17%
Holding
61
New
9
Increased
14
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$19.2M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$15.7M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$14.3M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$10.9M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$10.9M

Top Sells

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$18.8M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$15.7M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$15.5M
4
HALO icon
Halozyme
HALO
+$12.5M
5
AMGN icon
Amgen
AMGN
+$6.92M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$36.2M 9.57%
393,000
-51,000
-11% -$4.3M
GILD icon
2
Gilead Sciences
GILD
$185B
$25.1M 6.63%
387,784
+39,500
+11% +$2.55M
REGN icon
3
Regeneron Pharmaceuticals
REGN
$83.1B
$20.7M 5.48%
43,800
+32,300
+281% +$15.7M
NBIX icon
4
Neurocrine Biosciences
NBIX
$15.9B
$20.1M 5.32%
207,000
+183,000
+763% +$19.2M
EXEL icon
5
Exelixis
EXEL
$13.7B
$20M 5.3%
886,534
+360,000
+68% +$8.13M
PTCT icon
6
PTC Therapeutics
PTCT
$5.99B
$19.3M 5.11%
408,000
+75,000
+23% +$4.45M
SGEN
7
DELISTED
Seagen Inc. Common Stock
SGEN
$18.5M 4.88%
133,000
+67,500
+103% +$10.9M
VRTX icon
8
Vertex Pharmaceuticals
VRTX
$139B
$18.3M 4.85%
85,322
-12,000
-12% -$2.64M
ALNY icon
9
Alnylam Pharmaceuticals
ALNY
$31.7B
$15.4M 4.06%
108,800
+72,500
+200% +$10.9M
IONS icon
10
Ionis Pharmaceuticals
IONS
$10.4B
$15M 3.97%
333,781
+256,000
+329% +$14.3M
CCXI
11
DELISTED
ChemoCentryx, Inc.
CCXI
$14.8M 3.91%
288,600
+33,000
+13% +$1.99M
BIIB icon
12
Biogen
BIIB
$32.7B
$13.6M 3.59%
48,500
+15,700
+48% +$4.23M
BHVN
13
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$12.1M 3.19%
176,400
-24,000
-12% -$1.94M
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$11.5M 3.05%
67,400
– –
AMGN icon
15
Amgen
AMGN
$236B
$10.7M 2.83%
43,000
-29,000
-40% -$6.92M
QURE icon
16
uniQure
QURE
$3.44B
$9.49M 2.51%
282,034
+254,534
+926% +$9.12M
XLRN
17
DELISTED
Acceleron Pharma
XLRN
$8.2M 2.17%
60,500
-10,500
-15% -$1.36M
TPTX
18
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$7.71M 2.04%
81,541
-32,000
-28% -$3.81M
INCY icon
19
Incyte
INCY
$25.9B
$6.34M 1.68%
78,000
– –
ILMN icon
20
Illumina
ILMN
$34.4B
$6.26M 1.66%
+16,756
New +$6.83M
KALV
21
DELISTED
KalVista Pharmaceuticals
KALV
$5.49M 1.45%
214,533
+37,100
+21% +$975K
DCPH
22
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$4.48M 1.19%
100,000
+50,000
+100% +$2.33M
UTHR icon
23
United Therapeutics
UTHR
$22.7B
$4.45M 1.18%
+26,600
New +$4.44M
BMRN icon
24
BioMarin Pharmaceuticals
BMRN
$12.6B
$4.17M 1.1%
55,156
-192,428
-78% -$15.7M
PTGX icon
25
Protagonist Therapeutics
PTGX
$9.68B
$3.94M 1.04%
152,000
– –
1
2 3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q1 2021 Portfolio in Review

As of Q1 2021, International Biotechnology Trust held 61 positions worth $378M, up 3.3% from $366M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

International Biotechnology Trust deployed $42.8M of net new capital in Q1 2021, opening 9 new positions and adding to 14 existing holdings. Its largest new stake was Illumina: 16,756 shares worth $6.26M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Acadia Pharmaceuticals, an estimated $18.8M trimmed.

  • International Biotechnology Trust's largest Q1 2021 buy was Illumina: 16,756 shares worth $6.26M.
  • International Biotechnology Trust added most to Neurocrine Biosciences in Q1 2021, an estimated $19.2M increase.
  • International Biotechnology Trust's biggest Q1 2021 reduction was Acadia Pharmaceuticals, cutting an estimated $18.8M.
  • International Biotechnology Trust fully exited Alexion Pharmaceuticals in Q1 2021, selling an estimated $15.5M.
  • International Biotechnology Trust's ten largest holdings make up 55% of its $378M portfolio in Q1 2021.
  • International Biotechnology Trust opened 9 new positions and closed 5 in Q1 2021.
  • International Biotechnology Trust's portfolio value rose 3.3% quarter-over-quarter to $378M.

Based on International Biotechnology Trust's 13F filing for Q1 2021, filed 17 May 2021.